Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2010

Open Access 01-10-2010 | Research article

Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells

Authors: Bin Qin, Kun Cheng

Published in: Breast Cancer Research | Issue 5/2010

Login to get access

Abstract

Introduction

IκB kinase ε (IKKε) is a member of the IKK family that plays an important role in the activation of NF-κB. Overexpressed in more than 30% of breast cancers, IKKε has been recently identified as a potential breast cancer oncogene. The purpose of the present study is to examine the therapeutic potential of IKKε siRNA on human breast cancer cells.

Methods

Eight siRNAs targeting different regions of the IKKε mRNA were designed, and the silencing effect was screened by quantitative real-time RT-PCR. The biological effects of synthetic siRNAs on human breast cancer cells were investigated by examining the cell proliferation, migration, invasion, focus formation, anchorage-independent growth (via soft agar assay), cell cycle arrest, apoptosis (via annexing binding), NF-κB basal level, and NF-κB-related gene expressions upon the IKKε silencing.

Results

Silencing of IKKε in human breast cancer cells resulted in a decrease of focus formation potential and clonogenicity as well as in vitro cell migration/invasion capabilities. Moreover, knockdown of IKKε suppressed cell proliferation. Cell cycle assay showed that the anti-proliferation effect of IKKε siRNA was mediated by arresting cells in the G0/G1 phase, which was caused by downregulation of cyclin D1. Furthermore, we demonstrated that silencing of IKKε inhibited the NF-κB basal activity as well as the Bcl-2 expression. Significant apoptosis was not observed in breast cancer cells upon the silencing of IKKε. The present study provided the first evidence that silencing IKKε using synthetic siRNA can inhibit the invasiveness properties and proliferation of breast cancer cells.

Conclusions

Our results suggested that silencing IKKε using synthetic siRNA may offer a novel therapeutic strategy for breast cancer.
Appendix
Available only for authorised users
Literature
1.
Chau TL, Gioia R, Gatot JS, Patrascu F, Carpentier I, Chapelle JP, O'Neill L, Beyaert R, Piette J, Chariot A: Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated?. Trends Biochem Sci. 2008, 33: 171-180. 10.1016/j.tibs.2008.01.002.CrossRefPubMed
2.
Kishore N, Huynh QK, Mathialagan S, Hall T, Rouw S, Creely D, Lange G, Caroll J, Reitz B, Donnelly A, Boddupalli H, Combs RG, Kretzmer K, Tripp CS: IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme IKK-2: comparative analysis of recombinant human IKK-i, TBK-1, and IKK-2. J Biol Chem. 2002, 277: 13840-13847. 10.1074/jbc.M110474200.CrossRefPubMed
3.
Sethi G, Sung B, Aggarwal BB: Nuclear factor-κB activation: from bench to bedside. Exp Biol Med (Maywood). 2008, 233: 21-31. 10.3181/0707-MR-196.CrossRef
4.
Adli M, Baldwin AS: IKK-i/IKKε controls constitutive, cancer cell-associated NF-κB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem. 2006, 281: 26976-26984. 10.1074/jbc.M603133200.CrossRefPubMed
5.
Peters RT, Liao SM, Maniatis T: IKKε is part of a novel PMA-inducible IκB kinase complex. Mol Cell. 2000, 5: 513-522. 10.1016/S1097-2765(00)80445-1.CrossRefPubMed
6.
Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-Kishikawa T, Hill DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts TM, Lander ES, Polyak K, Hahn WC: Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 2007, 129: 1065-1079. 10.1016/j.cell.2007.03.052.CrossRefPubMed
7.
Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, Hahn WC, Cantley LC: Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKε promotes cell transformation. Mol Cell. 2009, 34: 461-472. 10.1016/j.molcel.2009.04.031.CrossRefPubMedPubMedCentral
8.
Kravchenko VV, Mathison JC, Schwamborn K, Mercurio F, Ulevitch RJ: IKKi/IKKε plays a key role in integrating signals induced by pro-inflammatory stimuli. J Biol Chem. 2003, 278: 26612-26619. 10.1074/jbc.M303001200.CrossRefPubMed
9.
Tenoever BR, Ng SL, Chua MA, McWhirter SM, Garcia-Sastre A, Maniatis T: Multiple functions of the IKK-related kinase IKKε in interferon-mediated antiviral immunity. Science. 2007, 315: 1274-1278. 10.1126/science.1136567.CrossRefPubMed
10.
Peant B, Diallo JS, Dufour F, Le Page C, Delvoye N, Saad F, Mes-Masson AM: Over-expression of IκB-kinase-epsilon (IKKε/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines. Prostate. 2009, 69: 706-718. 10.1002/pros.20912.CrossRefPubMed
11.
Eddy SF, Guo S, Demicco EG, Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE: Inducible IκB kinase/IκB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-κB activation in breast cancer cells. Cancer Res. 2005, 65: 11375-11383. 10.1158/0008-5472.CAN-05-1602.CrossRefPubMed
12.
Sithanandam G, Fornwald LW, Fields J, Anderson LM: Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene. 2005, 24: 1847-1859. 10.1038/sj.onc.1208381.CrossRefPubMed
13.
Liu TG, Yin JQ, Shang BY, Min Z, He HW, Jiang JM, Chen F, Zhen YS, Shao RG: Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer. Cancer Gene Ther. 2004, 11: 748-756. 10.1038/sj.cgt.7700753.CrossRefPubMed
14.
15.
Cheng K, Fraga D, Zhang C, Kotb M, Gaber AO, Guntaka RV, Mahato RI: Adenovirus-based vascular endothelial growth factor gene delivery to human pancreatic islets. Gene Ther. 2004, 11: 1105-1116. 10.1038/sj.gt.3302267.CrossRefPubMed
16.
17.
Ma L, Teruya-Feldstein J, Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007, 449: 682-688. 10.1038/nature06174.CrossRefPubMed
18.
Tiang JM, Butcher NJ, Minchin RF: Small molecule inhibition of arylamine N-acetyltransferase type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun. 2010, 393: 95-100. 10.1016/j.bbrc.2010.01.087.CrossRefPubMed
19.
Pearson G, English JM, White MA, Cobb MH: ERK5 and ERK2 cooperate to regulate NF-κB and cell transformation. J Biol Chem. 2001, 276: 7927-7931. 10.1074/jbc.M009764200.CrossRefPubMed
20.
Imoto M, Doki Y, Jiang W, Han EK, Weinstein IB: Effects of cyclin D1 overexpression on G1 progression-related events. Exp Cell Res. 1997, 236: 173-180. 10.1006/excr.1997.3713.CrossRefPubMed
21.
Musgrove EA, Lee CS, Buckley MF, Sutherland RL: Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA. 1994, 91: 8022-8026. 10.1073/pnas.91.17.8022.CrossRefPubMedPubMedCentral
22.
Tapia MA, Gonzalez-Navarrete I, Dalmases A, Bosch M, Rodriguez-Fanjul V, Rolfe M, Ross JS, Mezquita J, Mezquita C, Bachs O, Gascon P, Rojo F, Perona R, Rovira A, Albanell J: Inhibition of the canonical IKK/NFκB pathway sensitizes human cancer cells to doxorubicin. Cell Cycle. 2007, 6: 2284-2292. 10.4161/cc.6.18.4721.CrossRefPubMed
23.
Guo JP, Shu SK, He L, Lee YC, Kruk PA, Grenman S, Nicosia SV, Mor G, Schell MJ, Coppola D, Cheng JQ: Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol. 2009, 175: 324-333. 10.2353/ajpath.2009.080767.CrossRefPubMedPubMedCentral
24.
Renner F, Moreno R, Schmitz ML: SUMOylation-dependent localization of IKKε in PML nuclear bodies is essential for protection against DNA-damage-triggered cell death. Mol Cell. 2010, 37: 503-515. 10.1016/j.molcel.2010.01.018.CrossRefPubMed
25.
Basseres DS, Baldwin AS: Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene. 2006, 25: 6817-6830. 10.1038/sj.onc.1209942.CrossRefPubMed
26.
Sung B, Pandey MK, Nakajima Y, Nishida H, Konishi T, Chaturvedi MM, Aggarwal BB: Identification of a novel blocker of IκBα kinase activation that enhances apoptosis and inhibits proliferation and invasion by suppressing nuclear factor-κB. Mol Cancer Ther. 2008, 7: 191-201. 10.1158/1535-7163.MCT-07-0406.CrossRefPubMed
27.
Lee TK, Poon RT, Wo JY, Ma S, Guan XY, Myers JN, Altevogt P, Yuen AP: Lupeol suppresses cisplatin-induced nuclear factor-κB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res. 2007, 67: 8800-8809. 10.1158/0008-5472.CAN-07-0801.CrossRefPubMed
28.
Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA, Karin M: Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin. Nature. 2007, 446: 690-694. 10.1038/nature05656.CrossRefPubMed
29.
MacKeigan JP, Murphy LO, Blenis J: Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol. 2005, 7: 591-600. 10.1038/ncb1258.CrossRefPubMed
30.
Desagher S, Martinou JC: Mitochondria as the central control point of apoptosis. Trends Cell Biol. 2000, 10: 369-377. 10.1016/S0962-8924(00)01803-1.CrossRefPubMed
31.
Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, Ferrandina G, Gallo D, Ranelletti FO, Scambia G: Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol. 2003, 64: 51-58. 10.1124/mol.64.1.51.CrossRefPubMed
32.
Tophkhane C, Yang S, Bales W, Archer L, Osunkoya A, Thor AD, Yang X: Bcl-2 overexpression sensitizes MCF-7 cells to genistein by multiple mechanisms. Int J Oncol. 2007, 31: 867-874.PubMed
33.
Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, Sahin AA: The nuclear transcription factor κB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res. 2005, 11: 8398-8402. 10.1158/1078-0432.CCR-05-0885.CrossRefPubMed
34.
Emi M, Kim R, Tanabe K, Uchida Y, Toge T: Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res. 2005, 7: R940-R952. 10.1186/bcr1323.CrossRefPubMedPubMedCentral
35.
Julien T, Frankel B, Longo S, Kyle M, Gibson S, Shillitoe E, Ryken T: Antisense-mediated inhibition of the bcl-2 gene induces apoptosis in human malignant glioma. Surg Neurol. 2000, 53: 360-368. 10.1016/S0090-3019(00)00178-6. discussion 368-369CrossRefPubMed
36.
Lima RT, Martins LM, Guimaraes JE, Sambade C, Vasconcelos MH: Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther. 2004, 11: 309-316. 10.1038/sj.cgt.7700706.CrossRefPubMed
37.
Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, Ozpolat B: Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy. 2008, 4: 669-679.CrossRefPubMed
38.
Hsu SY, Kaipia A, McGee E, Lomeli M, Hsueh AJ: Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proc Natl Acad Sci USA. 1997, 94: 12401-12406. 10.1073/pnas.94.23.12401.CrossRefPubMedPubMedCentral
39.
Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994, 54: 1812-1817.PubMed
40.
Roy PG, Thompson AM: Cyclin D1 and breast cancer. Breast. 2006, 15: 718-727. 10.1016/j.breast.2006.02.005.CrossRefPubMed
41.
Guo JP, Shu SK, Esposito NN, Coppola D, Koomen JM, Cheng JQ: IKKε phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer. J Biol Chem. 2010, 285: 3676-3684. 10.1074/jbc.M109.078212.CrossRefPubMed
Metadata
Title
Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells
Authors
Bin Qin
Kun Cheng
Publication date
01-10-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2644

Other articles of this Issue 5/2010

Breast Cancer Research 5/2010 Go to the issue

Research article

Family history of later-onset breast cancer, breast healthy behavior and invasive breast cancer among postmenopausal women: a cohort study

Viewpoint

Mammary stem cells and cancer: roles of Wnt signaling in plain view

Research article

Regulation of breast cancer cell motility by T-cell lymphoma invasion and metastasis-inducing protein

Research article

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer

Research article

Akt is required for Stat5 activation and mammary differentiation

Research article

RARα1 control of mammary gland ductal morphogenesis and wnt1-tumorigenesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits